Project Grant R21EY037150
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $439K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- This federal Project Grant award of $764,881 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research to investigate the role of advanced glycation end products (AGEs) in primary open-angle glaucoma (POAG). The overarching hypothesis is that the accumulation of AGEs in the trabecular meshwork promotes extracellular matrix remodeling and cell dysfunction, leading to increased outflow resistance and elevated intraocular pressure in POAG. The research project has two...
- This $1,620,537 federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) supports research at Northwestern University to model aqueous humor outflow and develop a digital twin of the anterior eye to improve the understanding and treatment of glaucoma. The project aims to enhance minimally invasive glaucoma surgery (MIGS) efficacy by better characterizing the circumferential anatomy and pathophysiology of aqueous humor outflow, which currently limits the...
- The National Eye Institute (NEI) awarded a $451,000 Project Grant under the Vision Research federal grant program (CFDA 93.867) to The Regents of the University of California, San Francisco (UCSF) to conduct a multimodal characterization of a novel inherited mouse model of glaucoma. The research aims to evaluate structural and functional changes in the mouse model, including axonal degeneration, retinal ganglion cell loss, dendritic changes, and neuroinflammatory responses. It will also identify...
- This $417,162 Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) supports research on using optical techniques to detect early signs of glaucoma, the leading cause of irreversible blindness worldwide. The University of Houston System, the grantee, will conduct research to determine if changes in the birefringence (optical properties) of the lamina cribrosa and posterior eye structures can serve as sensitive early indicators of glaucoma before structural damage...
- This federal Project Grant award of $234,000.00 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to enhance stem cell restoration of intraocular pressure (IOP) homeostasis through senolytic treatments. The key goals are to study how senescent trabecular meshwork (TM) cells in glaucoma patients affect IOP regulation, and to explore whether clearing these senescent cells using senolytic drugs can improve the effectiveness of...
- This Project Grant award of $568,122.00, provided by the National Eye Institute (CFDA 93.867 - Vision Research), supports research at Baylor College of Medicine to unequivocally confirm the contribution of the neurovascular unit to glaucoma pathogenesis and identify endothelial cell-specific ligands with potential for neuroprotective therapy. The research aims to globally map ligands binding to ocular hypertension and healthy retinal cells, systematically identifying ocular...
- This Project Grant award for $679,159 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research on in vivo epigenetic reprogramming of retinal ganglion cells (RGCs) in aging mice with glaucoma. The research aims to identify new therapeutic targets for glaucoma that can protect and rejuvenate RGCs, which are specifically targeted and damaged in this disease leading to vision loss. The 4-year project, awarded to The Schepens Eye...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $481,250.00 to Vanderbilt University Medical Center to investigate the role of the ADAMTS10 protein in regulating transforming growth factor beta (TGF-β) signaling and its impact on retinal ganglion cell (RGC) degeneration in glaucoma. The key products and services to be delivered under this 2-year award include: Defining the mechanism by which ADAMTS10 promotes TGF-β signaling, including...
- This federal Project Grant awarded by the National Science Foundation (NSF) Engineering program (CFDA 47.041) aims to create innovative tools to understand neurodegeneration in glaucoma blindness. The $600,000 award, with a project period from Jul 1, 2025 to Jun 30, 2030, supports the development of an integrated platform that combines bioengineering tools and neurobiological studies. Key components include: (1) an injectable microbead-based in vivo flow occlusion model to replicate...